Bristol-Myers Squibb Company (BMY) Shares Sold by Willingdon Wealth Management
Willingdon Wealth Management lowered its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 46.1% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 65,516 shares of the biopharmaceutical company’s stock after selling 56,102 shares during the period. Bristol-Myers Squibb makes up 1.4% of Willingdon Wealth Management’s investment portfolio, making the stock its 14th biggest holding. Willingdon Wealth Management’s holdings in Bristol-Myers Squibb were worth $3,651,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. State Street Corp increased its stake in Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after acquiring an additional 1,223,457 shares during the period. Jennison Associates LLC increased its stake in Bristol-Myers Squibb by 5.4% in the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock valued at $1,288,179,000 after acquiring an additional 1,184,652 shares during the period. Ameriprise Financial Inc. increased its stake in Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after acquiring an additional 2,451,390 shares during the period. Legal & General Group Plc increased its stake in Bristol-Myers Squibb by 2.7% in the second quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock valued at $469,802,000 after acquiring an additional 217,920 shares during the period. Finally, Swiss National Bank increased its stake in Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock valued at $322,020,000 after acquiring an additional 1,267,900 shares during the period. 69.14% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at $60.86 on Friday. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The company has a market cap of $101,459.04, a P/E ratio of 20.94, a PEG ratio of 2.44 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the company earned $0.77 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% compared to the same quarter last year. analysts anticipate that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.
A number of analysts recently weighed in on the stock. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Jefferies Group LLC reissued a “buy” rating and issued a $72.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price on the stock. in a research note on Thursday, September 28th. Finally, Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $64.93.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Company (BMY) Shares Sold by Willingdon Wealth Management” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-shares-sold-by-willingdon-wealth-management/1694857.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.23% of the stock is owned by corporate insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.